IP Library Granted Patent US 8,628,966
Granted Patent B2
US 8,628,966 · App. 13/097,046 · Granted Jan 14, 2014

CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer

Inventors: Saswati Chatterjee (Altadena, CA); Laura Smith (Pasadena, CA); Kamehameha Wong (Altadena, CA)
Assignee: City of Hope
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,628,966
App. No.
13/097,046
Granted
Jan 14, 2014
Kind
B2
Abstract

Novel adeno-associated virus (AAV) isolates in nucleotide and amino acid forms and uses thereof are provided. The isolates show tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Discrete modified portions of the cap gene, VP1, VP2, and VP3, may be used alone or in combination in the present methods.

Claims (15)

1. A recombinant nucleotide sequence which encodes an amino acid sequence of an AAV capsid or modified VP1, VP2 or VP3 portion thereof, wherein said amino acid sequence comprises a sequence selected from the group of SEQ ID NOS: 2-17.

2. The recombinant nucleotide sequence of claim 1 , wherein an AAV vector comprises the nucleotide sequence.

3. The recombinant nucleotide sequence of claim 2 , wherein the AAV vector is packaged, isolated and purified.

4. The recombinant nucleotide sequence of claim 1 , wherein the nucleic acid sequence comprises a sequence selected from the group of SEQ ID NOS: 20-35.

5. A method of transducing a cell comprising administering an AAV vector to the cell, wherein the AAV vector comprises

(i) a recombinant nucleotide sequence which encodes an amino acid sequence of an AAV capsid or modified VP1, VP2 or VP3 portion thereof, wherein said amino acid sequence comprises a sequence selected from the group of SEQ ID NOS: 2-17; and

(ii) a transgene.

6. The method of claim 5 , wherein the cell is a stem cell and the transgene is a reprogramming gene for the induction of induced pluripotent stem cells.

7. The method of claim 6 , wherein the stem cell is a hematopoietic stem cell (HSC) or a mesenchymal stem cell.

8. The method of claim 7 , wherein the HSC is a CD34 + HSC.

9. The method of claim 5 , wherein transducing a cell results in a transient transduction of the cell with the transgene.

10. The method of claim 9 , wherein the transgene is a zinc finger.

11. The method of claim 9 , wherein the transient transduction is performed in vitro and length of transduction time is controlled by culture conditions.

12. The method of claim 5 , wherein the cell is a liver cell.

13. The method of claim 5 , wherein the cell is a joint tissue cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2011
From: CHATTERJEE, SASWATI; SMITH, LAURA; WONG, KAMEHAMEHA
To: CITY OF HOPE
Reel/Frame 026565/0253 →
Continuity (2)
Provisional Application 61330272 · Apr 30, 2010
Related Publication 20110294218A1 · Dec 1, 2011